Showing results (191-200 of 234) with videos related to

Sort By:
Pageof 24
Clinical and Translational Science|January 24, 2024
Teclistamab: Mechanism of action, clinical, and translational scienceYue Guo, Natalia A Quijano Cardé, Lijuan Kang, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 4, 2024
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamabMarie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, et al.
Cancer|November 14, 2023
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 studyAjay K Nooka, Cesar Rodriguez, María Victoria Mateos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 14, 2011
Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT)Joanne F Chou, Nancy A Kernan, Susan Prockop, et al.
Bone Marrow Transplantation|March 22, 2016
Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donorsP Anur, D N Friedman, C Sklar, et al.
The Oncologist|May 14, 2020
A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar CarcinomaImane El Dika, Robert J Mayer, Alan P Venook, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.
Leukemia & Lymphoma|November 30, 2017
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experienceLisa Giulino-Roth, Tara O'Donohue, Zhengming Chen, et al.
Harmful Algae|April 20, 2021
Harmful algal blooms and their effects in coastal seas of Northern EuropeBengt Karlson, Per Andersen, Lars Arneborg, et al.
Cancer|March 30, 2023
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myelomaThomas G Martin, Maria Victoria Mateos, Ajay Nooka, et al.
Pageof 24